摘要:
The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.
摘要:
Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
摘要:
Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
摘要:
By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
摘要:
Provided is a pharmaceutical composition for reducing the risk in a patient at high risk for occurrence and/or recurrence of a cardiovascular event by administering the composition to the patient with a high ratio of oleic acid to stearic acid in plasma. The pharmaceutical composition contains ethyl icosapentate as its effective component. The composition is expected to reduce the risk in the patient at high risk for occurrence and/or recurrence of a cardiovascular event, and particularly to have a preventive effect on occurrence and/or recurrence of a cardiovascular event in the patient with a high ratio of oleic acid to stearic acid in plasma.
摘要:
The present invention provides a new anti-tumor agent containing adiponectin as an active ingredient, particularly, an anti-tumor agent capable of inhibiting carcinogenesis in the liver, use of adiponectin as an anti-tumor agent, and a prophylactic or therapeutic method against a tumor using adiponectin. The administration form may be either oral administration, e.g., by tablets or parenteral administration, e.g., by injection; in the case of intravenous injection for inhibiting carcinogenesis in the liver, the dosage is 1 to 100 mg/kg/day per adult patient.
摘要翻译:本发明提供了含有脂联素作为活性成分的新抗肿瘤剂,特别是能够抑制肝脏致癌作用的抗肿瘤剂,使用脂联素作为抗肿瘤剂,以及用于预防或治疗方法 使用脂联素的肿瘤。 给药形式可以是口服给药,例如通过片剂或肠胃外给药,例如通过注射; 在静脉注射用于抑制肝脏致癌作用的情况下,每位成年患者的剂量为1至100mg / kg /天。
摘要:
By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
摘要:
Although it is known that adiponectin, which is adipose-specific protein, has effects of suppressing the proliferation and migration of vascular smooth muscle, an effect against arteriosclerosis, an effect of inhibiting the activation of monocytes and macrophages and an anti-inflammatory effect, its action on hepatic stellate cells has never been known hitherto. The present invention has elucidated that adiponectin inhibits the actions of TGFB and PDGF on hepatic stellate cells and thereby exerts effects of suppressing hepatic fibrosis and promoting the proliferation of normal hepatocytes.
摘要:
The present invention provides a new anti-tumor agent containing adiponectin as an active ingredient, particularly, an anti-tumor agent capable of inhibiting carcinogenesis in the liver, use of adiponectin as an anti-tumor agent, and a prophylactic or therapeutic method against a tumor using adiponectin. The administration form may be either oral administration, e.g., by tablets or parenteral administration, e.g., by injection; in the case of intravenous injection for inhibiting carcinogenesis in the liver, the dosage is 1 to 100 mg/kg/day per adult patient.
摘要翻译:本发明提供了含有脂联素作为活性成分的新抗肿瘤剂,特别是能够抑制肝脏致癌作用的抗肿瘤剂,使用脂联素作为抗肿瘤剂,以及用于预防或治疗方法 使用脂联素的肿瘤。 给药形式可以是口服给药,例如通过片剂或肠胃外给药,例如通过注射; 在静脉注射用于抑制肝脏致癌作用的情况下,每位成年患者的剂量为1至100mg / kg /天。
摘要:
Although it is known that adiponectin, which is adipose-specific protein, has effects of suppressing the proliferation and migration of vascular smooth muscle, an effect against arteriosclerosis, an effect of inhibiting the activation of monocytes and macrophages and an anti-inflammatory effect, its action on hepatic stellate cells has never been known hitherto. The present invention has elucidated that adiponectin inhibits the actions of TGFB and PDGF on hepatic stellate cells and thereby exerts effects of suppressing hepatic fibrosis and promoting the proliferation of normal hepatocytes.